Action Voyager Acquisition - VACH

Voyager Acquisition Corporation (VACH) Action

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

11,29

( 6,51% )

Prix Achat

10,34

Prix Vente

11,50

Volume échangé

2 714

9,86 Fourchette du Jour 11,6599

8,40 Plage de 52 semaines 15,68

Cap du marché

72,343M

Clôture Veille

10,60

Ouverture

9,86

Dernière Transaction

11.18

Dernière heure de transaction

20:04:42

Volume financier

US$ 29 649

VWAP

10,9244

Volume moyen (3 m)

US$ 17 909

Actions en circulation

6 407 685

Rendement du Dividende (LTM)

Ratio Cours sur Bénéfices

47,67

Bénéfice par action (BPA)

0,22

Chiffre d'affairess (LTM)

Bénéfice net (LTM)

6,74M

Voyager Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses in the healthcare or healthc... Voyager Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses in the healthcare or healthcare related sectors. Voyager Acquisition Corp. was incorporated in 2023 and is based in Brooklyn, New York. Show more

Secteur

Industrie

Site Web

www.voyageracq.com

Siège social

Brooklyn, United States

Fondé

2026

Voyager Acquisition Corporation est coté dans le secteur de la NASDAQ avec le ticker VACH. Le dernier cours de clôture d'Voyager Acquisition était de US$10,60. Au cours de la dernière année, les actions de Voyager Acquisition ont été négociées dans une fourchette de prix de US$ 8,40 à US$ 15,68.

Voyager Acquisition compte actuellement 6 407 685 actions en circulation. La capitalisation boursière d'Voyager Acquisition est de US$72,34 million. Voyager Acquisition a un ratio cours/bénéfice (ratio PE) de 47.67.

Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG

BROOKLYN, N.Y., March 13, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager” or the...

Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG

BROOKLYN, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager” or the...

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

ZURICH, July 17, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies...

VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform

ZURICH, May 29, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed...

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

ZURICH, May 20, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel...

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

ZURICH, SWITZERLAND, May 05, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and...

VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

VERAXA’s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug...

Voyager Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about September 30, 2024

BROOKLYN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) announced that holders of the units...

Voyager Acquisition Corp. Announces Closing of $253,000,000 Initial Public Offering

BROOKLYN, N.Y., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) today announced that it closed its...

Voyager Acquisition Corp. Announces Pricing of $220,000,000 Initial Public Offering

BROOKLYN, N.Y., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) announced today the pricing of its...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	1.43	14.5030425963	9.86	11.6599	9.3	8010	10.39576376	CS
4	-1.34	-10.6096595408	12.63	13.11	8.4	8881	10.59603782	CS
12	0.53	4.92565055762	10.76	15.68	8.4	14220	11.71886141	CS
26	0.72	6.81173131504	10.57	15.68	8.4	83114	10.75853269	CS
52	0.91	8.76685934489	10.38	15.68	8.4	53708	10.67657511	CS
156	1.33	13.3534136546	9.96	15.68	8.4	70240	10.35146983	CS
260	1.33	13.3534136546	9.96	15.68	8.4	70240	10.35146983	CS

VACH - Frequently Asked Questions (FAQ)

What is the current Voyager Acquisition Corporation share price?

The current share price of Voyager Acquisition Corporation is US$ 11,29

How many Voyager Acquisition Corporation shares are in issue?

Voyager Acquisition Corporation has 6 407 685 shares in issue

What is the market cap of Voyager Acquisition Corporation?

The market capitalisation of Voyager Acquisition Corporation is USD 72,34M

What is the 1 year trading range for Voyager Acquisition Corporation share price?

Voyager Acquisition Corporation has traded in the range of US$ 8,40 to US$ 15,68 during the past year

What is the PE ratio of Voyager Acquisition Corporation?

The price to earnings ratio of Voyager Acquisition Corporation is 47,67

What is the registered address of Voyager Acquisition Corporation?

The registered address for Voyager Acquisition Corporation is 131 Concord Street, Brooklyn, New York, 11201

What is the Voyager Acquisition Corporation website address?

The website address for Voyager Acquisition Corporation is www.voyageracq.com

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Voyager Acquisition Corporation (VACH)

Voyager Acquisition Corporation (VACH) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Voyager Acquisition Corporation

VACH Dernières nouvelles

Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG

Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

Voyager Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about September 30, 2024

Voyager Acquisition Corp. Announces Closing of $253,000,000 Initial Public Offering

Voyager Acquisition Corp. Announces Pricing of $220,000,000 Initial Public Offering

Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG

Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

VACH - Frequently Asked Questions (FAQ)

VACH Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Voyager Acquisition Corporation (VACH)

Voyager Acquisition Corporation (VACH) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Voyager Acquisition Corporation

VACH Dernières nouvelles

Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG

Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

Voyager Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about September 30, 2024

Voyager Acquisition Corp. Announces Closing of $253,000,000 Initial Public Offering

Voyager Acquisition Corp. Announces Pricing of $220,000,000 Initial Public Offering

Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG

Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

VACH - Frequently Asked Questions (FAQ)

VACH Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Pourquoi rejoindre ADVFN?

Tout ce dont les traders professionnels ont besoin.

Supprimer les publicités